{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:40:47Z","timestamp":1777934447118,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T00:00:00Z","timestamp":1586563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Intraperitoneal with intravenous chemotherapy (IP\/IV) is the recommended option for patients with stage III cancer with optimally debulked (&lt;1\u2009cm residual) disease based on randomized controlled trials and showing important improvements in overall survival and progression free survival. However, its application has not been largely adopted due to its difficult administration that requires a trained nurse staff. The aim of this work was to study the completion and the toxicity of an IP outpatient chemotherapy regimen in optimally debulked stage III ovarian cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A single-center, retrospective observational study in women with stage III ovarian cancer following optimal cytoreductive surgery (&lt;1 cm) followed by IP\/IV chemotherapy from 2009 to 2017. The IP\/IV regimen was as it follows: IV paclitaxel 175\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      in 3\u2009h, day 1; IP cisplatin (100\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \u2014until December 2013\u2014or 75\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), day 2; IP paclitaxel 60\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , day 8, each 21\u2009days for six cycles.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 60 patients received IP\/IV regimen. Of these, 41 patients (68.3%) completed the six IP chemotherapy cycles and 51 (84.9%) completed four or more cycles. Most of the adverse events reported were non-hematological and G1-2. There was no difference neither in adherence nor in the frequency of adverse events between both cisplatin groups. Despite a high rate of adverse events, IP chemotherapy can be delivered with a high completion rate and manageable toxicity to patients with optimally debulked ovarian cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220915953","type":"journal-article","created":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T04:56:49Z","timestamp":1586581009000},"page":"268-278","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5444-5836","authenticated-orcid":false,"given":"Octavio","family":"Ballesta-L\u00f3pez","sequence":"first","affiliation":[{"name":"Servicio de Farmacia, \u00c1rea del Medicamento, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asunci\u00f3n","family":"Albert-Mar\u00ed","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, \u00c1rea del Medicamento, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Borrell-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, \u00c1rea del Medicamento, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Meli\u00e1n-Sosa","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Salvador-Coloma","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Santaballa-Bertr\u00e1n","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Poveda-Andr\u00e9s","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, \u00c1rea del Medicamento, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,4,11]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"International Agency for Research on Cancer. Cancer today http:\/\/gco.iarc.fr\/today\/home (accessed 22 January 2020)."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt333"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2007.11.004"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000330"},{"key":"e_1_3_2_6_2","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer","volume":"62","author":"Dedrick RL","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, et\u00a0al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1\u201311.","journal-title":"Cancer Treat Rep"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/11598890-000000000-00000"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.01099.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052985"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.3494"},{"key":"e_1_3_2_11_2","unstructured":"NCI Clinical Announcement on Intraperitoneal Chemotherapy in Ovarian Cancer (January 5 2006) | NCI Clinical Announcement on Intraperitoneal Chemotherapy in Ovarian Cancer (January 5 2006) | CTEP https:\/\/ctep.cancer.gov\/highlights\/20060105_ovarian.htm (accessed 22 January 2020)."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31821ee777"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61157-0"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32259-7"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01568"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.10.012"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2654"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.07.129"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.05.023"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.2456"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjog.2013.12.010"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.000058"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e318234f833"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.11.009"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.091036"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(93)90169-G"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.12.017"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8823"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2012.10.005"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.11.005"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216656927"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0319"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.11.013"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182158640"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.03.027"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1188\/07.CJON.221-225"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1188\/08.CJON.265-271"},{"key":"e_1_3_2_38_2","first-page":"156","article-title":"Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?","volume":"25","author":"Echarri Gonzalez MJ","year":"2011","unstructured":"Echarri Gonzalez MJ, Green R, Muggia FM. Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when? Oncology (Williston Park, NY) 2011; 25: 156\u2013165, 170.","journal-title":"Oncology (Williston Park, NY)"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220915953","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220915953","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220915953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:22:51Z","timestamp":1777688571000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220915953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,11]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1177\/1078155220915953"],"URL":"https:\/\/doi.org\/10.1177\/1078155220915953","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,11]]}}}